Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International ...
Daily Maverick2d
How South Africa can help secure immediate, global access to HIV prevention drug lenacapavir
We need nothing less than disruptive action to ensure everyone who wants access to affordable lenacapavir can get it.
FiercePharma2d
Gilead's CAR-T sales stagnate as Trodelvy takes another impairment hit
Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...
Gilead Sciences, Inc. (GILD) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...
Gilead to present HIV research findings at conference
Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...
Q3 2024 Gilead Sciences Inc Earnings Call
Good afternoon, everyone, and welcome to Gilead's third-quarter 2024 earnings conference call. My name is Rebecca and I'll be your host for today in a moment. (Operator Instructions) I'll now hand the ...
BioSpace2d
Gilead Beats Q3 Expectations Fueled by HIV Drug Sales, Raises Full-Year Guidance
BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...
Why Gilead's Solid Q3 Earnings Could Point To A Dividend Surprise Next Year
Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio. Read why I ...
Gilead Sciences: Strong Financial Performance and Promising Pipeline Drive Buy Rating
Leerink Partners analyst Daina Graybosch has maintained their bullish stance on GILD stock, giving a Buy rating yesterday. Daina ...
Gilead increases 2024 outlook, expects new drug filing by end of year
Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...
Gilead Sciences Tops Estimates in Q3
Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.